Changes in the utilization of prenatal diagnosis

Obstetrics and Gynecology

Volumn 103, Issue 6, 2004, Pages 1255-1260

  Benn, Peter A ^a   Egan, James F X ^b   Fang, Min ^b   Smith Bindman, Rebecca ^b  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AMNIOCENTESIS; AMNION FLUID ANALYSIS; BLOOD ANALYSIS; CHORION VILLUS SAMPLING; CHROMOSOME ABERRATION; CYTOGENETICS; DOWN SYNDROME; ECHOGRAPHY; FEMALE; FETUS; HEALTH CARE DELIVERY; HEALTH CARE UTILIZATION; HEALTH CENTER; HUMAN; LABORATORY; MAJOR CLINICAL STUDY; MATERNAL AGE; NORMAL HUMAN; PATIENT REFERRAL; PRENATAL DIAGNOSIS; PRENATAL SCREENING; PRIORITY JOURNAL; REVIEW; SECOND TRIMESTER PREGNANCY; UNIVERSITY; ARTICLE; CHROMOSOME DISORDER; COHORT ANALYSIS; GENETIC SCREENING; HIGH RISK PREGNANCY; KARYOTYPING; PREGNANCY; RETROSPECTIVE STUDY; STATISTICAL MODEL; UNITED STATES; UTILIZATION REVIEW;

ADULT; AMNIOCENTESIS; CHORIONIC VILLI SAMPLING; CHROMOSOME DISORDERS; COHORT STUDIES; CONNECTICUT; DOWN SYNDROME; FEMALE; GENETIC SCREENING; HUMANS; KARYOTYPING; LINEAR MODELS; MATERNAL AGE; PREGNANCY; PREGNANCY, HIGH-RISK; REFERRAL AND CONSULTATION; RETROSPECTIVE STUDIES; ULTRASONOGRAPHY, PRENATAL;

EID: 3042531626     PISSN: 00297844     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.AOG.0000127008.14792.14     Document Type: Review

References (23)

1. American College of Obstetricians and Gynecologists. Prenatal diagnosis of fetal chromosomal abnormalities. ACOG Practice Bulletin 27. Washington, DC: ACOG; 2001.
2. American College of Medical Genetics. ACMG position statement on multiple marker screening in women 35 and older, 1994. Available at: http://www.acmg.net/resources/policies/pol-022.asp. Retrieved October 6, 2003.
3. Egan JFX, Benn P, Borgida AF, Rodis JF, Campbell WA, Vintzileos AM. Efficacy of screening for Down syndrome in the United States from 1974 to 1997. Obstet Gynecol 2000;96:979-85.
4. Benn PA, Fang M, Egan JFX, Horne D, Collins R. Incorporation of inhibin-A in second-trimester screening for Down syndrome. Obstet Gynecol 2003;101:451-4.
5. Wald NJ, Huttley WJ, Hackshaw AK. Antenatal screening for Down's syndrome with the quadruple test. Lancet 2003;361:835-6.
6. Snijders RJ, Noble P, Sebire N, Souka A, Nicolaides KH. UK multicentre project on assessment of risk of trisomy 21 by maternal age and fetal nuchal-translucency thickness at 10-14 weeks of gestation. Fetal Medicine Foundation First Trimester Screening Group. Lancet 1998;352:343-6.
7. Wald NJ, Kennard A, Hackshaw A, McGuire A. Antenatal screening for Down's syndrome. J Med Screen 1997;4: 181-246.
8. Shipp TD, Benacerraf BR. Second trimester ultrasound screening for chromosomal abnormalities. Prenat Diagn 2002;22:296-307.
9. Wald NJ, Cuckle HS, Densem JW, Nanchahal K, Royston P, Chard T, et al. Maternal serum screening for Down's syndrome in early pregnancy. BMJ 1988;297:883-7.
10. Haddow JE, Palomaki GE, Knight GJ, Cunningham GC, Lustig LS, Boyd PA. Reducing the need for amniocentesis in women 35 years of age or older with serum markers for screening. N Engl J Med 1994;330:1114-8.
11. Benn PA. Improved antenatal screening for Down's syndrome. Lancet 2003;361:794-5.
12. Chen J, Heffley D, Beazoglou T, Benn P. Utilization of amniocentesis by women screening positive for Down syndrome on the second-trimester triple test. Commun Genet 2000;3:24-30.
13. Benn PA. Advances in prenatal screening for Down syndrome: I. General principles and second trimester testing. Clin Chim Acta 2002;323:1-16.
14. Benn PA. Advances in prenatal screening for Down syndrome: II. First trimester testing and future directions. Clin Chim Acta 2002;324:1-11.
15. Egan JFX, Malakh L, Turner G, Markenson G, Wax J, Benn PA. Role of ultrasound for Down syndrome screening of the advanced maternal age population. Am J Obstet Gynecol 2001;185:1028-31.
16. Nyberg DA, Luthy DA, Resta RG, Nyberg BC, Williams MA. Age-adjusted ultrasound risk assessment for fetal Down's syndrome during the second trimester: description of the method and analysis of 142 cases. Ultrasound Obstet Gynecol 1998;12:8-14.
17. National Center for Health Statistics (US). Vital statistics of the United States, 1991-2001. Hyattsville, MD: Natality Data Set; 1997-2003.
18. Bray I, Wright DE, Davies C, Hook EB. Joint estimation of Down syndrome risk and ascertainment rates: a meta-analysis of nine published data sets. Prenat Diagn 1998;18: 9-20.
19. Cuckle H. Down syndrome fetal loss rate in early pregnancy. Prenat Diagn 1999;19:1177-9.
20. Benn PA, Ying J, Beazoglou T, Egan JFX. Estimates for the sensitivity and false-positive rates for second trimester serum screening for Down syndrome and trisomy 18 with adjustment for cross-identification and double-positive results. Prenat Diagn 2001;21:46-51.
21. The NICHD National Registry for Amniocentesis Study Group. Midtrimester amniocentesis for prenatal diagnosis: safety and accuracy. J Am Med Assoc 1976;236:1471-6.
22. Medical Research Council Working Party on Amniocentesis. An assessment of the hazards of amniocentesis. Br J Obstet Gynaecol 1978;85:1-41.
23. Tabor A, Madsen M, Obel EB, Bang J, Obel EB, Norgaard-Pedersen B. Randomized controlled trial of genetic amniocentesis in 4606 low-risk women. Lancet 1986;1: 1287-92.